NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Good post, Umibe.

Here are my opinions:
1. OS is a relatively simple metric. Hence the paper by LL et al. was able to deal with it.
2. PFS is a much more complicated metric, imo. If you represent the tumor response for each patient under the influence of soc + methylation + DcVax-L as a differential equation, there will be a transient response of the tumor as well as steady state response. If the transient response shows some progression, but in the steady state there is no progression of the tumor, would some one consider it progression-free? At what point in time does steady state PFS begin?
3. To me it is very hard to imagine that the trial succeeded in OS without it succeeding in PFS in the steady state.

I am going back to bed and will see you all in the morning. I couldn't resist responding to this post.